Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death

Immunopharmacol Immunotoxicol. 1992;14(4):737-48. doi: 10.3109/08923979209009231.

Abstract

Experiments were performed to analyze the possible effect of the immunomodulating agent Pidotimod (3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid) on mouse Natural Killer (NK) cell activity and glucocorticoid hormone(GCH)-induced thymocyte apoptosis. The results indicate that in vivo treatment with Pidotimod (200 mg/Kg ip for 5 days) causes a significant increase in NK activity and in vitro treatment produces a significant reduction of dexamethasone-induced thymocyte apoptosis. This inhibition appears to be dose-dependent and is also evident against TPA or Ca(++)ionophore-induced apoptosis.

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Apoptosis / drug effects*
  • Calcium / physiology
  • Cellular Senescence / drug effects
  • Cytotoxicity, Immunologic / drug effects*
  • Killer Cells, Natural / drug effects*
  • Mice
  • Mice, Inbred C3H
  • Pyrrolidonecarboxylic Acid / analogs & derivatives*
  • Pyrrolidonecarboxylic Acid / pharmacology
  • Spleen
  • T-Lymphocytes / drug effects*
  • Thiazoles / pharmacology*
  • Thiazolidines

Substances

  • Adjuvants, Immunologic
  • Thiazoles
  • Thiazolidines
  • pidotimod
  • Calcium
  • Pyrrolidonecarboxylic Acid